Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price dropped 1.8% during mid-day trading on Wednesday. The company traded as low as GBX 5.40 and last traded at GBX 5.50. 1,291,653 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 2,352,387 shares. The stock had previously closed at GBX 5.60.
Shield Therapeutics Price Performance
The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16. The company has a 50 day moving average price of GBX 4.92 and a 200 day moving average price of GBX 6.28. The firm has a market cap of £58.00 million, a PE ratio of -5.40 and a beta of 1.77.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
